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Abstract
Objectives: In this study, we aimed to evaluate the relationship between three-dimensional echocardiography (3DE)determined myocardial contraction fraction (MCF) and functional capacity in heart failure with reduced ejection fraction
(HFrEF) patients. The MCF is a volumetric index of myocardial function, deﬁned as stroke volume ratio to myocardial
volume (MV). Functional capacity was evaluated by a 6-min walk test (6MWT), and health-related quality of life
(HRQOL) was assessed by the Minnesota Living with Heart Failure Questionnaire (MLHFQ). In view of cardiac
remodeling, we hypothesized that MCF would be superior to left ventricular ejection fraction (LVEF) in predicting
functional capacity in HFrEF patients.
Methods: The study was conducted on thirty HFrEF patients with an LVEF of no more than 40% with NYHA functional
class I-III. Each patient performed, on the same day, the MLHFQ, 6MWT (to calculate the 6-min walk distance “6MWD”),
and an ECG gated echocardiographic study including 3DE-determined MCF. MV was calculated as 3DE determined LV
mass divided by the speciﬁc gravity of the myocardium.
Results: Our results showed that MCF is inversely correlated with the Minnesota score (r ¼ ¡0.6, p < 0.001) and
positively correlated with 6MWD (r ¼ 0.65, p < 0.001). However, no signiﬁcant relationship existed between LVEF and
MLHFQ score or 6MWD. In a multivariate model, MCF was shown to be an independent echocardiographic predictor
(besides pulmonary artery systolic pressure) of 6MWD; however, LVEF failed to offer such potential.
Conclusion: Among various echocardiographic parameters, MCF can be considered a volumetric index superior to
LVEF in predicting functional capacity in HFrEF patients.
Keywords: Myocardial contraction fraction, Heart failure, HFrEF, Functional capacity, MLHFQ, Six-minute walk test

1. Introduction

H

eart failure (HF) is a signiﬁcant global health
burden affecting 1e2% of the population and
more than an estimated 64 million people worldwide and resulting in more than one million hospitalizations annually [1]. Adults with HF have a
lower health-related quality of life (HRQOL) and
more inferior functional capacity than those without
HF. Both HRQOL and functional capacity are

predictors of HF outcomes (hospitalization and
mortality). Because of such association, these variables have become important endpoints of HF care.
Numerous investigators have tested and subsequently approved interventions to improve
HRQOL, functional status, and survival. Functional
status was shown to be a mediator between HRQOL
and cardiac event-free survival [2].
Pathologic left ventricular remodeling is the ﬁnal
common pathway to HF, whether the initial
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stimulus is chronic pressure or chronic volume
overload, genetically determined cardiomyopathy,
or myocardial infarction. Cardiac remodeling is a
major determinant of the clinical course of HF [3].
As cardiac remodeling of the left ventricle results in
alteration of intracardiac geometry and hemodynamics, echocardiography represents a cornerstone
imaging investigation tool that is crucial in the
diagnosis and management of HF patients. Assessment of left ventricular systolic function by left
ventricular ejection fraction (LVEF) has been traditionally utilized as an index of myocardial performance and a crucial metric in assessing HF patients'
progression. However, cardiologists have tried to
solve the long-standing dilemma of discrepant
functional capacity in patients with HFrEF and
numerically similar LVEF [4].
Myocardial contraction fraction (MCF), deﬁned as
the ratio of stroke volume (SV) to end-diastolic
myocardial volume “MV” (MCF ¼ SV/MV), has
been suggested as an easily determined volumetric
LV index. In this ratio, the SV is a measure of the
amount of shortening and thickening that has
occurred. Its ratio to MV is an index of the fractional
shortening of the myocardium in volumetric terms
and hence a measure of ventricular function [5]. It
has been shown that decreased cardiac magnetic
resonance imaging (CMR)ederived MCF is an independent predictor of future hard cardiovascular
disease events in initially healthy adults [6].
In reference to CMR, LV volumes and mass
calculated from three-dimensional (3D) echocardiography showed signiﬁcantly better agreement and
lower intra- and inter-observer variability than twodimensional (2D) echocardiography [7e9]. Whether
3D-echocardiography-derived MCF is associated
with functional capacity in patients with HFrEF and
hence a useful prognostic metric in this patient
population has not been studied yet.

2. Materials and methods
2.1. Patient selection
The study included 30 patients with chronic stable
heart failure, aged 18e65 years with a left ventricular ejection fraction (LVEF)  40% and NYHA class
I-III, receiving the standard treatment for HF at the
cardiac rehabilitation outpatient clinic of the University Hospital. Patients with acute decompensated
HFrEF, hospitalization within the past six months,
atrial ﬁbrillation or frequent extrasystoles, recent
acute coronary syndrome, acute myocarditis, or
heart failure due to valvular heart disease were
excluded from the study group. Patients were also
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excluded if they had poor epicardial or endocardial
visualization on 2D echocardiography of 3
contiguous segments using a 17-segment model or
complex congenital heart disease.
MCF from the HFrEF patients was compared with
that obtained from 30 healthy subjects with no history of cardiovascular disease or systemic illness,
with a normal physical examination, electrocardiogram, and echocardiographic examination (control
group).
This study was approved by our institutional review board and local ethical committee. Informed
consent was obtained from all enrolled individuals.
The procedures followed during the study were in
accordance with the ethical standards of the Helsinki Declaration of the World Medical Association.
2.2. Study group
2.2.1. Clinical data collection
Patient characteristics were obtained, including
cardiac risk factors (hypertension, diabetes mellitus,
smoking) and etiology of heart failure (ischemic or

non-ischemic). Ischemic etiology was determined
by either angiographic evidence of 70% lesion in
one or more of the three major coronary vessels,
history of previous myocardial infarction or revascularization procedure, or evident signiﬁcant
perfusion defect concomitant with ischemic
symptoms.
2.2.2. Assessment of functional capacity
Functional capacity was objectively assessed by a
6-min walk test (6MWT) performed on the same day
of clinical and echocardiographic assessment. The
test was conducted along a long, ﬂat, straight,
enclosed corridor with a hard surface. We used a 30m walking corridor with marks on the wall every
3 m. The patient had to turn around at the end of
each 30 m to complete one lap at 60 m.
2.2.3. Assessment of health-related quality of life
Health-related Quality of life (HRQoL) was
assessed on the same day of clinical and echocardiographic assessment with the “Minnesota living
with heart failure questionnaire” (MLHFQ). The
MLHFQ is a self-administered disease-speciﬁc
questionnaire for patients with HF, comprising 21
items rated on six-point Likert scales, from 0 (none)
to 5 (very much), representing physical (8 items,
range 0e40), emotional (5 items, range 0e25) and
socioeconomic (8 items, range 0e40) degrees of
impact of HF on HRQoL, thus provides a total score
(range 0e105, from best to worst HRQoL) [10,11].
2.2.4. Echocardiographic assessment
All echocardiographic measurements were obtained on the same day of the 6MWT by an observer
blinded to the test result data. Transthoracic echocardiographic examination with machine-integrated
ECG recording was performed, mainly with the
patients lying in the left lateral decubitus position.
The study was conducted using a commercially
available echocardiography system (Vivid E9, GE
Vingmed, Horten, Norway) equipped with a 2.5MHz multifrequency phased array transducer and a
3V cardiac vector array probe with a frequency
range of 1.5e3.6 MHz. All echocardiographic measurements in this study were done in concordance
with the recommendations for performance and
reporting of the American Society of Echocardiography (ASE) [12].
2.2.4.1. Two dimensional (2D) echocardiographic parameters. Digital routine grayscale two dimensional
(2D) and tissue Doppler cine loops including midleft ventricular short-axis views at the papillary
muscle level and standard apical views (4- chamber,

17

2-chamber, and long axis) were obtained at endexpiratory apnea from standard apical views at a
depth of 12e20 cm. Gain settings were adjusted for
routine grayscale 2D imaging to optimize endocardial deﬁnitions. All parameters were averaged over
three heart cycles. The following parameters were
obtained: Left ventricular end-diastolic diameter
(LVEDD), left ventricular end-systolic diameter
(LVESD), interventricular septal wall thickness
(SWT), posterior wall thickness (PWT), and anteroposterior left atrial diameter (LAD). 2D-derived
left ventricular mass was calculated based on the
following formula:
2D-derived LV mass (cube formula): 0.8 (1.04
([LVEDD þ PWT þ SWT]3-[LVEDD]3)) þ 0.6 g. [12].
Using modiﬁed biplane Simpson's, left ventricular
end-diastolic volume (LVEDV2D), left ventricular
systolic end-systolic volume (LVESV2D), left atrial
volume (LAV), and left ventricular ejection fraction
(LVEF2D) were calculated. Tricuspid Annular Plane
Systolic Excursion (TAPSE) and E/E' (peak transmitral ﬂow velocity in early diastole (E)/average of
lateral and septal early mitral annular tissue velocity) were calculated.
2.2.4.2. Three-Dimensional (3D) Echocardiographic parameters. Real-time 3D echocardiography LV full
volume acquisition was performed from the apical
window during held end-expiration. To ensure the
inclusion of the entire left ventricle within the pyramidal scan volume, data sets were acquired using
the wide-angle mode, wherein four-beat ECG-gated
sub-volumes were obtained from the apical view,
during an end-expiratory apnea to generate the fullvolume data set using the wide-angle default during
a single 5- to 7-sec breath-hold.
The acquired loops included end-diastole and
end-systole and spanned the ventricle from the
inferior surface of the aortic valve to the epicardial
apex about one centimeter apart. The acquired full
volume cine loops were digitally stored and transmitted to the attached workstation for ofﬂine analysis using the 4DAutoLVQ package (Echo PAC
v110.1.3, GE-Healthcare, Horten, Norway) [12,13].
Data sets acquired with Vivid E9 were analyzed
ofﬂine. The end-diastolic frames needed for contour
detection were automatically displayed in a quad
view (Fig. 1). Manual alignment by pivoting and
translating the four-chamber plane was performed
to align the three apical views. The corresponding
intersection line of all planes was placed in the
middle of the LV cavity, crossing the LV apex and
the center of the mitral valve in each view. We used
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Fig. 1. Displays 3D acquisition from two different patients of LV volumes (LVEDV3D and LVESV3D), LVEF3D, SV, and LVM parameters
(LVM3Dand LVMI3D).

the semi-automated option to identify a ﬁtting
geometric model subsequently. The software
required the manual input of only two points (one
point at the apex and another at the tip of the mitral
leaﬂet) on the end-diastolic and end-systolic frames
of the four-chamber view slice.
End-diastole was identiﬁed automatically by the
software as the time point in which the LV cavity is
the largest and end-systole as the time point at
which the cavity was smallest. The LV outﬂow tract,
papillary muscles, and trabeculae were included
within the LV cavity. Finally, the program generated
an endocardial surface shell from which LV volumes
(LVEDV3D and LVESV3D) and LV ejection fraction
(LVEF3D) were calculated. After LV volumes and
ejection fraction measurements, an automatic trace
of the epicardial border at end-diastole was displayed to identify the region of interest required for
LV mass. Epicardial trace could be manually
adjusted with the same point-click method, and LV
mass parameters were derived (LVM3D and
LVMI3D).
Myocardial contraction fraction (MCF) was calculated as the ratio of SV to end-diastolic myocardial
volume “MV” (MCF ¼ SV/MV), where
MV ¼ LVM3D/1.05 (the speciﬁc gravity of the
myocardium) [14].
2.3. Statistical analysis
Categorical variables were expressed as numbers
(%), and continuous variables were represented as
mean ± SD. Qualitative variables were compared
using the Chi-squared test. The independent sample t-test and ANOVA were used to compare the
quantitative variables of different groups. Linear
regression was used for correlation analyses,
expressed as Pearson correlation coefﬁcients. For an
analysis of the independent determinants,

multivariate linear and logistic regression analysis
models based on stepwise selection were generated
for variables that showed linear correlations.
Receiver operating characteristic curve analysis was
used to determine the best cutoff values. For all
tests, a p-value < 0.05 was considered statistically
signiﬁcant. All the analyses were performed using
the commercially available statistical software
(SPSS, Inc., Chicago, IL, USA).

3. Results
Due to poor epicardial or endocardial deﬁnition,
two patients from the screened control group and
three patients from the screened study group were
excluded. Although there was no difference between the HF and control groups regarding age and
gender (P > 0.05), there were signiﬁcant differences
in all echocardiographic parameters denoting the
occurrence of remodeling in the HF group. HF
group had signiﬁcantly greater LV internal dimensions, wall thickness, LV volumes (2D and 3D),
LV mass index (2D and 3D), LA anteroposterior
diameter & volumes. Besides, the HF group had
signiﬁcantly lower LVEF (either by 2D or 3D measurements) and RV function (TAPSE), besides
higher E/e' and SPAP as shown in table 1. Regarding
MCF, there was a highly signiﬁcant difference between the HF group and controls, where the mean
MCF of HF patients was lower than that of control
(0.28 ± 0.5% vs. 0.56 ± 0.09%, P < 0.001) as shown in
table 1.
3.1. Association of echocardiographic parameters
with HRQOL and functional capacity
3.1.1. Quality of life (QOL)
Although there was a lack of signiﬁcant correlation between LVEF2D and MLHFQ, there was a
signiﬁcant negative correlation between LVEF3D

Table 1. Demographic and echocardiographic characteristics of heart failure and control groups.
Variables

Heart failure group

Demographic data
Age
59.6 ± 6.5
Gender (Males)
25 (83.3%)
2D- echocardiographic parameters
LVEDD (mm)
59.63 ± 10.66
LVESD (mm)
49.10 ± 10.97
SWT (mm)
10.17 ± 0.99
PWT (mm)
10.30 ± 1.32
LVEDV2D (ml)
178.83 ± 64.86
LVESV2D (ml)
128.40 ± 58.59
LVEF2D (%)
30.00 ± 7.38
LVMI2D (g/m2)
143.34 ± 52.75
LAD (mm)
41.50 ± 6.86
LAV (ml)
65.93 ± 30.63
E/E0
8.86 ± 2.92
TAPSE (mm)
18.40 ± 3.91
SPAP (mmHg)
42.32 ± 11.08
3D-echocardiographic parameters
LVEDV3D (ml)
191.57 ± 75.59
LVESV3D (ml)
137.63 ± 66.72
LVEF3D (%)
31.03 ± 7.27
LVMI3D (g/m2)
110.6 ± 38.31
MV (ml)
196.95 ± 61.8
MCF
0.28 ± 0.05

and MLFHQ (r ¼ 0.39, P ¼ 0.031) as well as between MCF and MLHFQ (r ¼ 0.6, P < 0.001), as
shown in ﬁgure 2. Also, a signiﬁcant positive correlation was witnessed between SPAP and MLHFQ
(r ¼ 0.69, P < 0.001), as shown in table 2.
3.1.2. Functional capacity (FC)
It has been demonstrated that MCF is positively
correlated with 6MWD (r ¼ 0.65, P < 0.001), as
shown in ﬁgure 1. However, no signiﬁcant relationship existed between LVEF (whether 2D or 3D)
and functional capacity assessed by 6MWD. Multivariate analysis revealed that besides age, SPAP and
MCF were the only independent echocardiographic
predictors of 6MWTD; however, E/e' and LVEF

Control group

X2 or t

P-value

58.9 ± 6
24 (80%)

0.454
0.111

0.651
0.739

47.33 ± 4.2
31.87 ± 3.80
9.23 ± 0.94
9.20 ± 1.13
92.93 ± 10.30
34.87 ± 4.94
62.80 ± 3.69
89.35 ± 15.37
31.60 ± 5.15
29.80 ± 6.18
5.14 ± 0.89
20.17 ± 1.76
22.77 ± 3.03

5.883
8.129
3.763
3.477
7.164
8.713
20.835
5.382
6.323
6.334
6.690
2.256
6.191

<0.001
<0.001
<0.001
0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.028
<0.001

98.20 ± 13.21
38.57 ± 7.36
62.83 ± 3.04
66.16 ± 5.46
107.81 ± 3.85
0.56 ± 0.09

6.665
8.084
22.101
6.290
7.884
14.022

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

(whether 2D or 3D-measured) did not show statistical signiﬁcance, as shown in table 3.
It is worth mentioning that regarding MCF; there
was a moderately signiﬁcant correlation between
MCF and LVEF2D (r ¼ 0.48, P ¼ 0.008) and between
MCF and LVEF3D (r ¼ 0.6, P < 0.001).

Table 2. Correlation between some echocardiographic parameters and
MLHFQ.
LVEF2D
LVEF3D
SPAP
MCF

r

P-value

0.297
0.394
0.693
0.603

0.111
0.031*
<0.001*
<0.001*

Fig. 2. Shows plot charts showing a signiﬁcant inverse correlation between myocardial contraction fraction (MCF) and MLHFQ score (a) and a
signiﬁcant positive correlation between MCF and 6MWD.
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Table 3. Linear regression analysis for 6MWD.
Unstandardized
Coefﬁcients

Standardized
Coefﬁcients

B

Beta

Standard Error

(Constant)
494.177
Age
1.687
SPAP
4.582
MCF
644.343
LVEF2D
0.360
LVEF3D
1.527
E/e'
4.596
Dependent Variable: 6MWD

125.872
1.553
0.908
256.450
2.940
3.134
3.409

0.127
0.599
0.370
0.032
0.135
0.162

t

P-value

3.926
1.086
5.046
2.513
0.122
0.487
1.348

0.001*
0.295
<0.001*
0.024*
0.904
0.633
0.198

95% Conﬁdence
Interval for B
Lower Bound

Upper Bound

225.887
4.997
6.518
97.734
6.627
8.206
11.861

762.467
1.623
2.646
1190.953
5.906
5.153
2.669

patients, 53.3%) with 6MWD exceeding 300 m. Both
groups were subsequently compared regarding demographic data, risk factors, and echocardiographic
parameters, as shown in table 4. Patients with poor
FC were signiﬁcantly older with higher BMI and
worse HRQOL (higher MLHFQ score). Concerning
echocardiographic parameters, although they lacked
a signiﬁcant difference in LVEF (2D or 3D), LAV or
LVMI, the poor FC subgroup had a signiﬁcantly
lower MCF, higher E/E0 , and SPAP.
3.2. Cutoff Value of Myocardial contraction
Fractional (MCF) to predict good and poor
functional capacity
Fig. 3. Shows ROC curve to determine the cutoff value of Myocardial
contraction Fractional (MCF) to discriminate between good and poor
functional capacity HF subgroups.

As most previous studies utilizing the 6MWT
classiﬁed the HF patients using a cutoff of 300 m for its
prognostic implications, we dichotomized the 30 patients in our study into two groups according to the
6MWD, a poor FC subgroup (14 patients, 46.7%) with
6MWD below 300 m and a good FC subgroup (16

Receiver Operating Characteristic (ROC) curve
was done to determine the best MCF cutoff value
between both subgroups. The best cutoff value of
MCF was 0.28 (28%) with a sensitivity of 81.25% and
speciﬁcity of 78.57% (Fig. 3).

4. Discussion
Several studies have attempted to stratify HF patients according to their functional status to follow
their clinical status over time and assess the effects

Table 4. Comparison between poor and good functional capacity subgroups regarding age, BMI, and echocardiographic parameters.
Age
BMI
MLHFQ score
LVEF2D
LAV
E/e'
TAPSE
SPAP
LVEDV3D
LVESV3D
LVEF3D
LVMI2D
LVMI3D
MCF

Poor FC subgroup (46.7%)

Good FC subgroup (53.3%)

t

P-value

63.36 ± 4.77
28.71 ± 3.79
56.00 ± 18.14
29.07 ± 6.85
68.79 ± 34.04
10.23 ± 3.14
17.21 ± 3.22
47.86 ± 9.63
212.79 ± 85.72
157.50 ± 75.85
29.07 ± 7.48
154.35 ± 58.78
124.74 ± 43.16
0.25 ± 0.05

56.38 ± 6.15
25.94 ± 3.51
24.56 ± 6.72
30.81 ± 7.94
63.44 ± 28.20
7.67 ± 2.16
19.44 ± 4.26
32.63 ± 5.23
173.00 ± 62.37
120.25 ± 54.11
32.75 ± 6.86
133.70 ± 46.60
98.226 ± 29.56
0.313 ± 0.04

3.43
2.08
6.46
0.64
0.47
2.64
1.60
4.11
1.47
1.56
1.41
1.07
1.98
3.60

0.002*
0.047*
<0.01*
0.528
0.641
0.014*
0.122
0.001*
0.154
0.129
0.171
0.292
0.057
0.001*

of therapeutic interventions and rehabilitation programs. Besides being considered salient endpoints
in HF studies, both quality of life and functional
capacity are essential clinical and prognostic measures in HF patients. [15] As a validated prognostic
tool, the Minnesota Living with Heart Failure
Questionnaire (MLHFQ) was used to evaluate
HRQOL. We used the 6-min walk test (6MWT) to
assess exercise capacity at submaximal exercise
levels with high test-retest reliability and a proven
sensitive index to assess response to therapeutic
interventions in HF. It has been shown to be an
independent predictor of mortality and mortality or
hospitalization for cardiovascular reasons in patients with stable systolic HF. [16e18]
Lower levels of functional capacity (a distance
<300 m during 6MWT) have proven to be predictive
of both mortality (total or cardiovascular) and
morbidity (hospitalization for worsening heart failure) in HFrEF patients. [19,20] Therefore, we used
300 m in the 6MWT as an arbitrary cutoff value to
stratify the HF study group according to their
walking capability.
Assessment of left ventricular systolic function by
LVEF has been traditionally utilized as an indispensable metric of myocardial performance and
progression in patients with HFrEF [21,22]. For
years, cardiologists have tried to solve the longstanding challenging dilemma of discrepant functional capacity in patients with HFrEF and similar
chronic ventricular dysfunction. Several explanations have been suggested that attributed this
discrepancy to the fact that LVEF is inﬂuenced by
loading conditions and does not account for
myocardial volume. Failure of LVEF to accurately
predict patient functional capacity and hence prognosis has stimulated researchers to search for other
alternative echocardiographic indices that can
possess the potential to predict LV myocardial performance, integrating structure and function.
Recent theories in the pathophysiology of HF have
posed intense emphasis upon cardiac remodeling.
Several therapeutic interventions have been devised
to reverse this adverse remodeling and hence
prognosis. Therefore, we opted for an echocardiographic dimensionless index that encompasses
myocardial volume instead of chamber size to be
more representative of the remodeling process. This
index was ﬁrst coined by King et al. called
myocardial contraction fraction (MCF) is deﬁned as
MCF ¼ SV/MV [5].
As myocardial volume is constant from enddiastole to end-systole, indexing SV to myocardial
volume represents a volumetric index of myocardial
function (shortening) independent of the geometric
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inﬂuence of chamber volume. It could be intuitively
viewed as a hybrid measure of an LV functional
index (SV) and a structural measure (LV mass),
which could be potentially sensitive to varying
physiologic and pathologic conditions [6]. Thus, it
represents a metric of LV myocardial performance
per volume of myocardial ﬁber. Consequently, a
decrease in MCF, which is positively correlated with
global longitudinal strain on echocardiography [23],
indicates abnormal myocardial shortening and reﬂects abnormalities in myocardial properties
induced by hypertrophy, inﬂammation, microvascular dysfunction, and alterations of the
interstitium.
MCF thus seems to offer a clear, simple deﬁnition
with a relatively easily acquired echocardiographic
parameter. Being a dimensionless index analogous
to LVEF, MCF easily permits comparing myocardial
shortening between subjects. Owing to its inclusion
of myocardial volume in its calculation, MCF has
been recently studied in cardiomyopathy, namely
hypertrophic cardiomyopathy by Shimada et al., AL
cardiac amyloidosis by Tendler et al., transthyretin
amyloidosis by Rubin et al., diabetic cardiomyopathy by Bertoni et al. and non-ischemic dilated cardiomyopathy by Arenja [6,24e28]. Arenja et al.
demonstrated that a depressed MCF level was
associated with a higher risk of the combined
outcome of cardiac death, heart transplantation,
sudden cardiac death aborted by appropriate
implantable cardioverter-deﬁbrillator discharge due
to ventricular tachycardia or ﬁbrillation, and hospitalization due to congestive heart failure among individuals with non-ischemic dilated cardiomyo
pathy (LVEF<55%) [28].
In our study, we aimed to assess the relationship
between 3D-echocardiographically derived MCF
and functional capacity in patients with HFrEF,
assessed by 6MWT and HRQOL assessed by
MLHFQ. To our knowledge, there were no previously published studies performed to interrogate
such a relationship in patients with HFrEF.
MCF requires accurate measurement of both SV
and MV. 3D echocardiography has been resorted to
in our study, as 3D echocardiography and cardiac
myocardial resonance (CMR) have been shown to
yield equivalent results in assessing chamber volume and myocardial volume that are superior to Mmode and 2D echocardiographic techniques. This
may be accounted for by the fact that 3D echocardiography avoids geometric assumptions and errors
in image plane position and reduces sampling
errors.
In our study, the calculated MCF of the control
group was 0.56 ± 0.09, which is comparable to that
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achieved by Chuang et al., who estimated MCF in
healthy men and women using CMR (males
0.52 ± 0.11 and females 0.58 ± 0.13). King et al. study
yielded 3D echo-derived MCF of 0.44 ± 0.07 in
normal sedentary individuals and 0.50 ± 0.05 in
adult athletes [5]. It has been demonstrated that
MCF, like LVEF, could discriminate the HF group
from the healthy group, which was shown to be of
highly signiﬁcant difference statistically (0.28 ± 0.05
in the HF group versus 0.56 ± 0.09 in the control
group, P < 0.001). This can be explained by
remodeling in the HF group with signiﬁcantly
higher LV volumes and mass with lower SV than
the control group [6].
In the HF study group, the calculated MCF was
associated with quality of life and functional capacity. It has been shown that MCF is inversely
correlated with the MLHFQ score (r ¼ 0.6,
p < 0.001) and positively correlated with 6MWD
(r ¼ 0.65, p < 0.001). However, no signiﬁcant relationship existed between LVEF2D by biplane
Simpson's and either MLHFQ or 6MWT. Indeed,
MCF was shown to be an independent predictorbesides SPAP- of 6MWT; however, LVEF failed to
offer such potential.
In our study, to further distinguish HF patients
with good functional capacity from those with poor
functional capacity according to arbitrary walking
distance of 300 m in the 6MWT, an MCF of 28% as a
cutoff value showed a sensitivity of 81% and a
speciﬁcity of 79%. This further strengthens the hypothesis that MCF may be a superior metric-better
than LVEF- in predicting the functional capacity of
the HFrEF population. These results are commensurate with the conclusion achieved by Shimada
et al. and Maurer et al. that showed that MCF is
associated with subjective functional capacity in
hypertrophic cardiomyopathy much more strongly
than LVEF [26,29].

5. Limitations of the study
The conducted study has some limitations, as it
is a single-center study that comprised a relatively small sample size. Poor endocardial or
epicardial visualization precluded involving a
minority of patients. It also did not interrogate the
long-term prognostic utility of this echocardiographic index. Further larger multicenter studies
are warranted to further elaborate the capability
of MCF as a promising echocardiographic index
in the prediction of functional capacity as well as
overall survival and prognosis in patients with
HFrEF.

6. Conclusion
MCF can be considered a volumetric echocardiographic index superior to LVEF in predicting functional capacity in HFrEF patients.
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